U.S. Fund A Shares (without sales charge) posted a return of -0.04% in second quarter of 2026. Read more here.
THC raised its 2026 outlook after Q2 earnings and revenues beat expectations, driven by strong same-facility growth and disciplined expense management.
Multiple members of Congress disclose buying SpaceX stock, even some who aren't big fans of Elon Musk.
HCA Healthcare's (HCA) Q2 results were largely in line with the company's pre-release but Health Ins
UBS analyst A.J. Rice maintains HCA Healthcare (NYSE:HCA) with a Buy and lowers the price target from $635 to $579.
HCA's Q2 results beat expectations. Company resets 2026 guidance on HIX headwinds and decline in surgeries.
Morgan Stanley analyst Craig Hettenbach maintains HCA Healthcare (NYSE:HCA) with a Underweight and lowers the price target from $425 to $380.
HCA Healthcare's Q2 earnings beat expectations with $20.23B in revenue and adjusted earnings of $7.59 per share. Analysts lower price targets.
View interactive chart, options flow, and AI analysis for HCA on Zorveq Finance.
Open HCA Chart & Analysis →